Carter HB - Search Results

1

Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Huang MM, Macura KJ, Landis P, Epstein JI, Gawande R, Carter HB, Mamawala M. Huang MM, et al. Among authors: carter hb. Urology. 2020 Apr;138:84-90. doi: 10.1016/j.urology.2020.01.001. Epub 2020 Jan 15. Urology. 2020. PMID: 31954166

2

Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.

Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, Gorin MA, Pavlovich CP. Schwen ZR, et al. Among authors: carter hb. BJU Int. 2020 Sep;126(3):373-378. doi: 10.1111/bju.15101. Epub 2020 Jun 2. BJU Int. 2020. PMID: 32367635

3

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Carter HB, Walsh PC, Landis P, Epstein JI. Carter HB, et al. J Urol. 2002 Mar;167(3):1231-4. J Urol. 2002. PMID: 11832703

4

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

Fang J, Metter EJ, Landis P, Carter HB. Fang J, et al. Among authors: carter hb. Urology. 2002 Jun;59(6):889-93; discussion 893-4. doi: 10.1016/s0090-4295(02)01646-1. Urology. 2002. PMID: 12031375

5

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Khan MA, et al. Among authors: carter hb. J Urol. 2003 Dec;170(6 Pt 1):2274-8. doi: 10.1097/01.ju.0000097124.21878.6b. J Urol. 2003. PMID: 14634395

6

Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle?

Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Hernandez DJ, et al. Among authors: carter hb. J Urol. 2005 Feb;173(2):446-9. doi: 10.1097/01.ju.0000151135.80249.c9. J Urol. 2005. PMID: 15643199

7

Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?

Carter HB, Landis P, Wright EJ, Parsons JK, Metter EJ. Carter HB, et al. J Urol. 2005 Jun;173(6):2040-3. doi: 10.1097/01.ju.0000158372.45211.47. J Urol. 2005. PMID: 15879821

8

Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy.

Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Epstein JI, et al. Among authors: carter hb. Urology. 2005 Aug;66(2):356-60. doi: 10.1016/j.urology.2005.03.002. Urology. 2005. PMID: 16040085

9

Delayed versus immediate surgical intervention and prostate cancer outcome.

Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Warlick C, et al. Among authors: carter hb. J Natl Cancer Inst. 2006 Mar 1;98(5):355-7. doi: 10.1093/jnci/djj072. J Natl Cancer Inst. 2006. PMID: 16507832 Free PMC article.

10

Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.

Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML. Magheli A, et al. Among authors: carter hb. J Urol. 2007 Oct;178(4 Pt 1):1277-80; discussion 1280-1. doi: 10.1016/j.juro.2007.05.153. Epub 2007 Aug 14. J Urol. 2007. PMID: 17698121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters